Key result
Metformin significantly decreased the expression levels of ANGPTL2, p-Akt, and p-Foxol in ovarian tissues and improved insulin resistance in a rat model of PCOS.
Why the study?
The study investigated the expression of angiopoietin-like protein 2 (ANGPTL2) in ovarian tissues of rat models of polycystic ovary syndrome (PCOS) and its correlation with PCOS.
Does metformin reduce ANGPTL2 expression and improve insulin resistance in a rat model of polycystic ovary syndrome?
Does metformin reduce ANGPTL2 expression and improve insulin resistance in a rat model of polycystic ovary syndrome?
p-value: p=<0.05
Metformin improves insulin resistance and reduces ANGPTL2 expression in a rat model of PCOS, suggesting ANGPTL2 may participate in PCOS development via the PI3K/Akt pathway.
BACKGROUND: This study investigated the expression of angiopoietin-like protein 2 (ANGPTL2) in the tissues of rat models of polycystic ovary syndrome (PCOS) and its correlation with PCOS. METHODS: Six-weeks-old female specific pathogen-free rats (n = 60) were divided into blank control, PCOS model, and metformin groups (n = 20/group). After 21 days of metformin intervention, the serum sex hormones, fasting blood glucose, fasting insulin, and insulin resistance (IR) of rats in each group were measured. The mRNA levels of ANGPTL2, Foxol, and Akt in the ovarian tissues were monitored by real-time fluorescence quantitative PCR. RESULTS: Compared with the control group, the levels of serum sex hormones, fasting blood glucose, fasting insulin, and IR in the model group showed significant increases, and the levels of ANGPTL2, Foxol, and Akt in the ovarian tissue also showed significant increases. Compared with the PCOS group, the serum sex hormones, fasting blood glucose, fasting insulin, and IR of rats in the metformin group were significantly decreased, and the levels of ANGPTL2, Foxol, and Akt in ovarian tissues also showed significant decreases. CONCLUSIONS: These findings suggest that ANGPTL2 might participate in the development of PCOS through the PI3K/Akt signaling pathway. Metformin improves IR by reducing the expression of ANGPTL2, thus improving the endocrine environment of PCOS and might change the disease outcome.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied Polycystic ovary syndrome (PCOS) (n=60). Metformin vs. Normal saline (PCOS model group) was evaluated on Expression levels of ANGPTL2, p-Akt, and p-Foxol in ovarian tissue (p=<0.05). Metformin significantly decreased the expression levels of ANGPTL2, p-Akt, and p-Foxol in ovarian tissues and improved insulin resistance in a rat model of PCOS.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: